Core Viewpoint - Qianhong Pharmaceutical has reached a settlement with Jianyuan Trust to recover half of its investment in the "Chuangying 51" trust plan after a five-year dispute, highlighting the ongoing challenges faced by companies in managing trust investments and the impact of external economic conditions on asset performance [2][3][4]. Group 1: Settlement Details - On August 14, Qianhong Pharmaceutical announced it had reached a settlement with Jianyuan Trust regarding the "Chuangying 51" trust plan, resulting in a one-time payment of 56.9943 million yuan, which will be recognized as approximately 48.45 million yuan in profit for the 2025 fiscal year [2][5]. - The total investment in the two trust products purchased in 2018 amounted to 340 million yuan, with both products experiencing overdue payments [3][4]. - The settlement allows Qianhong to retain part of the trust beneficiary rights, indicating a strategy to balance risk while recovering some capital [6]. Group 2: Background of Trust Products - The "Chuangying 51" trust plan was set to mature on December 29, 2019, while the "Ruiying 64" plan was due on August 15, 2019, but both faced overdue payments due to the underlying assets' lack of liquidity and the borrower's financial difficulties [3][4]. - The total amount involved in the lawsuits against Jianyuan Trust was approximately 376.1866 million yuan, with overdue principal totaling 340 million yuan [4]. Group 3: Industry Context - The trend of companies facing challenges with trust investments is not isolated, as evidenced by other firms like Hengyin Technology and Chengdu Road and Bridge, which have also reported significant overdue amounts from trust products [7]. - The current economic environment has led to a preference for lower-risk fixed-income products among listed companies, with 36 companies reportedly investing a total of approximately 8.9 billion yuan in trust products since early 2025, reflecting a shift in investment strategy [7].

Core Viewpoint - Qianhong Pharmaceutical reached a settlement with Jianyuan Trust regarding a payment dispute from a trust plan purchased in 2018, resulting in a one-time payment of 56.9943 million yuan, which will contribute approximately 48.45 million yuan to the company's 2025 profit [1][4]. Group 1: Qianhong Pharmaceutical - Qianhong Pharmaceutical invested 170 million yuan in the "Anxin Chuangyin 51 Hao" trust plan, which was originally due on December 29, 2019 [4]. - After a prolonged legal battle lasting five years, the company agreed to withdraw its lawsuit in exchange for half of the remaining principal and earnings, amounting to 56.9943 million yuan [4]. - The expected profit increase of approximately 48.45 million yuan will be recorded in the 2025 profit statement [4]. Group 2: Jianyuan Trust - Jianyuan Trust reported a total revenue of 150 million yuan for the first half of 2025, marking an 84.89% year-on-year increase, and a net profit of 40 million yuan, up 13.36% [4][5]. - The company added 117 new trust projects in the first half of 2025, corresponding to a new trust scale of 1,080.01 billion yuan, reflecting a 785% year-on-year growth [5]. - As of June 30, 2025, Jianyuan Trust's managed trust assets reached 3,378.91 billion yuan, a 33.44% increase from the beginning of the year [5]. Group 3: Financial Performance and Business Development - In 2024, Jianyuan Trust achieved total revenue of 310 million yuan, with a net profit of 53 million yuan, representing a 25.15% year-on-year growth [7]. - The company’s solid business became a significant pillar, with interest income from proprietary business increasing by 12% to 32.5149 million yuan [7]. - Jianyuan Trust's trust asset management scale reached 2,532 billion yuan by the end of 2024, with a substantial growth of 78% from the beginning of the year [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002550 证券简称：千红制药 公告编号：2025-022 常州千红生化制药股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）第六届董事会第九次会议通知于2025年 8月8日通过邮件方式发出，会议于2025年8月13日在公司会议室以现场结合通讯表决的方式召开，会议 应出席董事9人，实际出席董事9人，其中宁敖先生、任胜祥先生、高玉玉女士以通讯表决方式出席。会 议由董事长王耀方先生召集并主持。本次会议的通知、召开以及董事出席人数和表决人数符合《公司 法》等法律法规和本公司《公司章程》的有关规定。 二、董事会会议审议情况 表决结果：同意9票，反对0票，弃权0票，议案获得通过。 2025年8月13日，经双方友好协商，公司与建元信托股份有限公司就创赢51号信托计划理财产品纠纷案 （案号（2020）沪74民初3号）达成和解并签署了《和解协议》。该协议签署当日，建元信托向公司支 付和解款 ...